Why is the Mesoblast (ASX:MSB) share price blasting 10% higher today?

It's a good day to be a shareholder in the regenerative medicine company.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price is shooting higher today despite the company's silence.

In fact, the market hasn't heard any price-sensitive news from the biotechnology company in two weeks.

Still, the company's stock is well and truly in the green today. At the time of writing, the Mesoblast share price is $1.75, 9.69% higher than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is currently up 1.17%. Meanwhile, the All Ordinaries Index (ASX: XAO) has gained 1.29%.

Let's take a look at the latest news from the company.

What's going on with the Mesoblast share price?

At its current share price, Mesoblast has now officially recovered from its late-November dip.

The company released its results for the first quarter of financial year 2022 on 24 November.

Within them, it reported a US$2.3 million year-on-year revenue increase, bringing its takings for the quarter up to US$3.6 million.

The company also reduced its cash usage, its research and development expenses, and its manufacturing expenses.

Perhaps unsurprisingly, the market bid the Mesoblast share price higher on the back of its results, sending it to gain 1.7%. However, it tumbled 11.3% over the following 6 sessions.

Between then and now, the company has conducted its annual general meeting and announced findings regarding its Rexlemestrocel-L drug.

On Monday, the company announced the DREAM-HF Phase 3 trial of Rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) found the greatest benefit from Rexlemestrocel-L is in HFrEF patients with diabetes, ischemia, or both.

While the news wasn't marked as price-sensitive, the Mesoblast share price gained 3.5% on Monday.

Finally, potentially helping Mesoblast along today is the broader healthcare sector's performance. The S&P/ASX 200 Health Care Index (ASX: XHJ) is currently up 0.6%, with nearly all its members recording gains.

While it's not as stellar as the broader market's performance, it's still good news for the company and its peers.

Yet. despite today's gains, the Mesoblast share price is still 22% lower than it was at the start of 2021. It's not all bad though — it's gained 5% since this time last month.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »